Artwork

Content provided by BioTech Nation Team and Moira Gunn. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by BioTech Nation Team and Moira Gunn or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

70% of Breast Cancers and a Link to Prostate Cancer... Dr. Sean Bohen, President & CEO, Olema Oncology

23:02
 
Share
 

Manage episode 414343056 series 3360496
Content provided by BioTech Nation Team and Moira Gunn. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by BioTech Nation Team and Moira Gunn or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

This week on BioTech Nation, we explore new efforts in treating cancer with Dr. Sean Bohen, President and CEO of Olema Oncology. We discuss progress in treating breast cancer, particularly ER+/HER2- breast cancer, which accounts for 70% of diagnoses this year. They examine the biology behind these cancers and how Olema's lead compound, palazestrant, works to antagonize the estrogen receptor, halting cancer cell growth. They also touch on the ongoing Phase 3 trial, OPERA-01, and the potential for combining palazestrant with other treatments.

  continue reading

90 episodes

Artwork
iconShare
 
Manage episode 414343056 series 3360496
Content provided by BioTech Nation Team and Moira Gunn. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by BioTech Nation Team and Moira Gunn or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

This week on BioTech Nation, we explore new efforts in treating cancer with Dr. Sean Bohen, President and CEO of Olema Oncology. We discuss progress in treating breast cancer, particularly ER+/HER2- breast cancer, which accounts for 70% of diagnoses this year. They examine the biology behind these cancers and how Olema's lead compound, palazestrant, works to antagonize the estrogen receptor, halting cancer cell growth. They also touch on the ongoing Phase 3 trial, OPERA-01, and the potential for combining palazestrant with other treatments.

  continue reading

90 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide